dc.contributor
Institut Català de la Salut
dc.contributor
[Parés-Badell O, Zules-Oña R, Pinós L, Vivet-Escalé M] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Armadans L, Borrás-Bermejo B, Otero S, Rodrigo-Pendás JÁ, Martínez-Gómez X] Servei de Medicina Preventiva i Epidemiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat Docent, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Cossio-Gil Y] Unitat de Suport a la Decisió, Direcció de Sistemes d’Informació, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Gestió del Sistema Sanitari, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Agustí A] Servei de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Aguilera C] Servei de Farmacologia Clínica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Campins M] Grup de Recerca d’Epidemiologia i Salut Pública, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Pares Badell, Oleguer
dc.contributor.author
Zules Oña, Ricardo Gabriel
dc.contributor.author
Armadans Gil, Lluis
dc.contributor.author
Pinos Tella, Laia
dc.contributor.author
Otero Romero, Susana
dc.contributor.author
Rodrigo Pendás, Jose Angel
dc.contributor.author
Vivet Escalé, Martí
dc.contributor.author
Cossio Gil, Yolima
dc.contributor.author
Agustí Escasany, Maria Antònia
dc.contributor.author
Martínez Gómez, Xavier
dc.contributor.author
Campins Martí, Magda
dc.contributor.author
Borras Bermejo, Blanca
dc.contributor.author
Aguilera, Cristina
dc.date.issued
2022-11-04T13:53:11Z
dc.date.issued
2022-11-04T13:53:11Z
dc.date.issued
2022-07-29
dc.identifier
Parés-Badell O, Zules-Oña R, Armadans L, Pinós L, Borrás-Bermejo B, Otero S, et al. Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination. Vaccines. 2022 Jul 29;10(8):1217.
dc.identifier
https://hdl.handle.net/11351/8403
dc.identifier
10.3390/vaccines10081217
dc.identifier
000845137300001
dc.description.abstract
COVID-19-vaccination; Adverse reactions; Booster dose
dc.description.abstract
Vacunación de COVID-19; Reacciones adversas; Dosis de refuerzo
dc.description.abstract
Vacunació de COVID-19; Reaccions adverses; Dosi de reforç
dc.description.abstract
The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.
dc.format
application/pdf
dc.publisher
Frontiers Media
dc.relation
Vaccines;10(8)
dc.relation
https://doi.org/10.3390/vaccines10081217
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
COVID-19 (Malaltia) - Vacunació
dc.subject
Vacunes - Efectes secundaris
dc.subject
Personal sanitari
dc.subject
DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
NAMED GROUPS::Persons::Occupational Groups::Health Personnel
dc.subject
ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.subject
DENOMINACIONES DE GRUPOS::personas::grupos profesionales::personal sanitario
dc.title
Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
